background
middl
east
respiratori
syndromecoronaviru
merscov
novel
zoonot
pathogen
although
potenti
merscov
transmiss
blood
transfus
clear
merscov
recogn
pathogen
concern
safeti
blood
suppli
especi
detect
whole
blood
serum
plasma
infect
individu
investig
efficaci
amotosalen
ultraviolet
light
uva
inactiv
merscov
freshfrozen
plasma
ffp
spike
recent
clinic
merscov
isol
infecti
genom
viral
titer
determin
plasma
inactiv
amotosalen
uva
treatment
plaqu
assay
revers
transcriptionquantit
polymeras
chain
reaction
respect
addit
residu
replic
live
viru
inactiv
examin
passag
permiss
vero
cell
abbrevi
cpe
cytopath
effect
ib
intercept
blood
system
merscov
middl
east
respiratori
syndromecoronaviru
pfu
plaqueform
unit
rtqpcr
revers
transcriptionquantit
polymeras
chain
reaction
sarscov
sever
acut
respiratori
syndromecoronaviru
mean
merscov
infecti
titer
pretreat
sampl
log
plaqueform
unit
pfu
ml
reduc
undetect
level
inactiv
amotosalen
uva
demonstr
mean
log
reduct
pfuml
furthermor
inocul
inactiv
plasma
vero
cell
result
cytopath
effect
cpe
even
day
incub
three
consecut
passag
detect
mer
rna
compar
pretreat
sampl
show
complet
cpe
within
day
postinocul
log
viral
rna
titer
rang
copi
ml
three
passag
conclus
data
show
amotosalenuva
treatment
potent
effect
way
inactiv
merscov
infecti
particl
ffp
undetect
level
minim
risk
possibl
transfusionrel
merscov
transmiss
ransfus
blood
compon
save
million
live
control
bleed
due
accid
surgeri
diseas
complic
howev
transmiss
pathogen
one
biggest
risk
transfus
labil
blood
compon
therefor
key
mission
blood
transfus
servic
provid
safe
blood
blood
product
screen
blood
product
reduc
spread
known
bloodborn
pathogen
hepat
b
c
virus
hbv
hcv
human
immunodefici
viru
hiv
human
tlymphotrop
viru
htlv
howev
known
unknown
pathogen
pose
threat
blood
suppli
region
differ
difficult
address
number
pathogen
screen
blood
bank
limit
number
blood
screen
assay
commerci
avail
therefor
pathogen
inactiv
offer
appeal
altern
blood
screen
serolog
nucleic
acid
test
nat
proactiv
natur
broad
spectrum
protect
offer
without
priori
character
unknown
pathogen
inde
pathogen
inactiv
technolog
develop
provid
safe
blood
product
reduc
need
implement
addit
screen
assay
middl
east
respiratori
syndromecoronaviru
merscov
zoonot
pathogen
endem
saudi
arabia
countri
arabian
peninsula
sinc
februari
merscov
respons
confirm
infect
includ
death
approx
mortal
rate
countri
case
confirm
infect
report
saudi
arabia
mortal
rate
approxim
merscov
caus
respiratori
ill
human
vari
asymptomat
mild
sever
pneumonia
elderli
patient
suffer
comorbid
risk
death
outcom
develop
sever
clinic
symptom
sever
pneumonia
extrapulmonari
manifest
major
rout
transmiss
mesrcov
via
droplet
fomit
persontoperson
contact
respiratori
system
well
via
direct
indirect
contact
zoonot
sourc
far
mer
case
link
resid
travel
saudi
arabia
sever
hospit
household
outbreak
report
saudi
arabia
well
south
korea
due
nosocomi
transmiss
close
contact
patient
howev
number
asymptomat
case
estim
much
higher
report
case
togeth
mild
case
may
increas
spread
viru
pose
signific
risk
blood
safeti
inde
presymptomat
asymptomat
donor
may
allow
donat
blood
donat
potenti
carri
viru
although
report
merscov
detect
blood
presymptomat
asymptomat
patient
report
merscov
case
due
humantohuman
transmiss
especi
inadequ
infect
control
measur
dromedari
camel
believ
reservoir
host
import
sourc
human
infect
specif
primari
index
case
contact
histori
infect
individu
like
direct
indirect
contact
dromedari
interestingli
current
regul
blood
donat
consid
recent
histori
contact
dromedari
reason
deferr
blood
donat
merscov
detect
varieti
sampl
infect
patient
includ
respiratori
sampl
serum
plasma
urin
stool
detect
merscov
rna
frequent
persist
respiratori
secret
high
viral
load
detect
viral
rna
plasma
serum
document
onethird
patient
show
associ
diseas
sever
reminisc
sever
acut
respiratori
syndromecoronaviru
sarscov
outbreak
start
china
led
global
humantohuman
spread
confirm
case
approxim
death
rate
sar
outbreak
viral
rna
detect
serum
sever
patient
transfusionassoci
transmiss
report
sarscov
disappear
quickli
merscov
continu
endem
arabian
peninsula
year
similar
sarscov
proven
evid
far
transfusiontransmit
merscov
infect
presenc
viral
rna
plasma
serum
acut
patient
rais
concern
especi
endem
area
like
saudi
arabia
fact
known
whether
presenc
viral
rna
blood
product
could
lead
transmiss
merscov
therefor
import
find
method
mitig
risk
associ
merscov
rna
presenc
blood
compon
proactiv
prevent
possibl
transmiss
merscov
contamin
blood
product
endem
region
elsewher
intercept
blood
system
ib
inactiv
pathogen
form
crosslink
monoadduct
nucleic
acid
use
amotosalen
photoact
psoralen
illumin
lowenergi
ultraviolet
uva
light
highli
specif
target
process
adduct
form
high
frequenc
nucleic
acid
thu
inhibit
transcript
replic
ib
food
drug
administrationapprov
pathogen
reduct
system
shown
inactiv
broad
spectrum
virus
bacteria
parasit
plasma
well
blood
product
without
affect
plasma
efficaci
patient
safeti
demonstr
clinic
evalu
hemovigil
data
multipl
countri
data
avail
inactiv
merscov
ib
howev
inactiv
sarscov
ib
relat
merscov
success
shown
rais
expect
suffici
inactiv
efficaci
therefor
aim
studi
evalu
efficaci
amotosalenuva
treatment
inactiv
merscov
human
apheresi
plasma
concentr
african
green
monkey
kidneyderiv
vero
cell
atcc
grown
maintain
previous
describ
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
human
merscov
isol
use
studi
character
previous
experi
involv
live
viru
conduct
biosafeti
level
facil
special
infecti
agent
unit
king
fahd
medic
research
center
king
abdulaziz
univers
jeddah
kingdom
saudi
arabia
follow
recommend
safeti
precaut
measur
merscov
amplif
cultur
done
previous
describ
viru
inocul
confluent
vero
cell
tissu
cultur
flask
multipl
infect
incub
humidifi
co
incub
hour
gentl
shake
everi
minut
subsequ
inoculum
replac
ml
viral
inocul
medium
dmem
fb
penicillinstreptomycin
mmoll
hepe
ph
cell
incub
humidifi
co
incub
hour
cell
show
cytopath
effect
cpe
supernat
collect
centrifug
remov
cellular
debri
minut
g
room
temperatur
viru
aliquot
store
titer
determin
plaqu
assay
whole
blood
unit
ml
collect
prepar
king
abdulaziz
univers
hospit
transfus
servic
jeddah
kingdom
saudi
arabia
voluntari
donor
briefli
blood
unit
centrifug
g
minut
separ
platelet
plt
rich
plasma
plt
rich
plasma
centrifug
g
minut
plasma
separ
plasma
bag
kept
blood
unit
screen
routin
hcv
antibodi
antigen
hbsag
hbc
antibodi
hiv
antibodi
htlv
antibodi
syphili
well
hcv
hbv
hiv
nat
two
unit
freshfrozen
plasma
ml
pool
experi
count
red
blood
cell
less
ml
pool
plasma
total
four
pool
n
use
studi
pool
plasma
unit
inocul
approxim
ml
merscov
stock
dilut
plasma
unit
inactiv
intercept
process
set
plasma
intercept
illumin
accord
manufactur
instruct
residu
amotosalen
free
photoproduct
remov
intercept
compound
adsorpt
devic
accord
manufactur
instruct
sampl
collect
test
follow
fig
posit
control
sampl
viru
stock
neg
control
sampl
plasma
pool
inocul
pretreat
sampl
inocul
plasma
pool
inactiv
sampl
treat
pool
plasma
sampl
store
test
plaqu
revers
transcriptionquantit
polymeras
chain
reaction
rtqpcr
assay
detect
merscov
replic
sampl
dilut
dilut
dmem
fb
inocul
confluent
vero
cell
sixwel
plate
incub
day
supernat
collect
dilut
dmem
fb
blindli
passag
two
time
passag
observ
cpe
collect
supernat
use
viral
rna
quantif
rtqpcr
vero
cell
prepar
ml
dmem
growth
medium
ml
seed
well
sixwel
plate
incub
overnight
sampl
serial
dilut
inocul
dmem
start
dilut
appli
confluent
vero
cell
monolay
well
incub
hour
gentl
shake
everi
minut
hour
inoculum
remov
replac
overlay
medium
dmem
agaros
incub
day
incub
overlay
remov
cell
fix
paraformaldehyd
minut
room
temperatur
stain
crystal
violet
stain
plaqu
examin
count
calcul
titer
plaqueform
unit
pfu
ml
previous
describ
experi
ml
ibstreat
plasma
test
plaqu
assay
detect
residu
infecti
viru
increas
dynam
rang
assay
neat
plasma
inocul
well
sampl
posit
neg
pretreat
inactiv
sampl
cell
supernat
rna
extract
previous
describ
use
viral
rna
mini
kit
qiagen
accord
manufactur
instruct
realtim
rtqpcr
perform
use
primer
probe
target
merscov
n
gene
previous
describ
specif
follow
forward
primer
revers
primer
probe
use
realtim
rtqpcr
perform
plate
fast
realtim
pcr
system
model
appli
biosystem
use
rtpcr
kit
quantitect
probe
qiagen
accord
manufactur
instruct
total
reaction
volum
rna
transcript
correspond
target
region
gener
use
cdna
synthesi
kit
superscript
rt
iii
invitrogen
plasmid
contain
merscov
n
gene
accord
manufactur
instruct
use
gener
standard
curv
estim
viral
rna
copi
number
sampl
previous
describ
run
includ
posit
viral
templat
control
notempl
neg
control
sampl
test
duplic
mean
report
log
copiesml
sampl
report
neg
cycl
threshold
valu
higher
cycl
studi
approv
biomed
ethic
committe
unit
king
abdulaziz
univers
hospit
approv
evalu
potenti
ib
inactiv
merscov
pool
plasma
merscov
viru
spike
pool
plasma
unit
treat
amotosalen
uva
light
viral
titer
pretreat
sampl
rang
log
pfuml
mean
titer
log
pfuml
tabl
treatment
result
detect
viabl
virus
inactiv
sampl
plaqu
assay
mean
reduct
log
pfuml
viral
infect
titer
four
independ
experi
experi
ad
fig
show
repres
result
plaqu
assay
therefor
larger
volum
inactiv
sampl
test
increas
sensit
dynam
rang
assay
shown
tabl
nonetheless
viabl
viru
detect
post
pathogen
inactiv
treatment
even
ml
plasma
test
viral
genom
titer
reduc
post
treatment
expect
tabl
togeth
data
show
amotosalenuva
light
pathogen
inactiv
technolog
inactiv
merscov
infecti
particl
spike
plasma
unit
next
analyz
presenc
potenti
low
level
replic
merscov
inactiv
plasma
unit
take
consider
genom
viral
titer
chang
treatment
tabl
end
vero
cell
inocul
plasma
sampl
pathogeninactiv
unit
incub
day
follow
two
addit
passag
day
incub
cpe
observ
neg
control
inactiv
sampl
even
day
postinocul
passag
three
time
compar
posit
pretreat
sampl
complet
destroy
cell
day
data
shown
confirm
result
viral
genom
rna
titer
measur
rtqpcr
supernat
collect
day
sampl
three
consecut
passag
shown
tabl
viral
genom
titer
posit
control
pretreat
sampl
rang
log
rna
copiesml
respect
three
passag
indic
presenc
replic
virus
sampl
hand
viral
rna
detect
supernat
collect
three
passag
neg
control
inactiv
sampl
confirm
complet
inactiv
infecti
merscov
plasma
current
known
pathogen
recogn
aabb
pathogen
concern
blood
transfus
howev
blood
donat
screen
small
number
pathogen
regular
basi
although
specif
pathogen
screen
test
blood
product
significantli
reduc
transfusionrel
infect
transmiss
wellrecogn
pathogen
hiv
hbv
hcv
still
report
mani
part
world
furthermor
emerg
andor
reemerg
pathogen
usual
zoonot
natur
pose
high
risk
blood
safeti
unpredict
natur
outbreak
errat
dynam
spread
repres
challeng
hurdl
prepared
plan
implement
safeti
measur
recent
exampl
emerg
zika
viru
mosquitoborn
flaviviru
transmiss
blood
transfus
outbreak
coronavirus
high
mortal
human
describ
sarscov
china
southeast
asia
merscov
middl
east
south
korea
detect
viral
rna
blood
patient
infect
sarscov
merscov
suggest
potenti
risk
transmiss
transfus
merscov
outbreak
south
korea
level
viral
load
rang
log
genom
copiesml
whole
blood
log
genom
copiesml
serum
anoth
studi
report
log
rna
copiesml
serum
infect
individu
correspond
approxim
infecti
titer
less
log
whole
blood
less
log
serum
accord
data
show
differ
genom
infecti
titer
tabl
use
ib
abl
show
mean
reduct
log
merscov
infecti
titer
rang
plasma
tabl
approxim
log
higher
minimum
reduct
titer
recommend
european
committe
blood
transfus
suggest
inactiv
capac
merscov
plasma
high
safeti
margin
contrast
infecti
titer
genom
titer
affect
slightli
pathogen
inactiv
treatment
tabl
amotosalenuva
process
effect
crosslink
nucleic
acid
break
strand
therefor
ensur
remain
amount
infecti
viru
particl
collect
supernat
passag
three
time
inactiv
day
absenc
cpe
even
day
incub
cultur
inocul
posttreat
sampl
suggest
infecti
merscov
remain
sampl
viral
genom
detect
supernat
cell
cultur
inocul
posttreat
sampl
even
multipl
passag
mostli
due
nonrepl
viral
genom
degrad
viral
rna
incub
period
contrast
pretreat
posit
control
sampl
show
high
level
viral
rna
incub
three
passag
demonstr
loss
infecti
viru
passag
success
inactiv
infecti
particl
ib
treatment
far
report
transmiss
merscov
sarscov
via
blood
transfus
despit
detect
viral
rna
serum
infect
individu
nonetheless
aabb
still
list
virus
pathogen
concern
blood
safeti
merscov
rna
detect
persist
patient
serum
day
diagnosi
evid
merscov
could
infect
replic
macrophag
dendrit
cell
cell
peripher
blood
therefor
realli
clear
whether
presenc
merscov
rna
blood
serum
plasma
could
consequ
transmiss
risk
merscov
transfus
apart
recent
larg
blood
virom
studi
found
blood
studi
popul
healthi
blood
donor
contain
genet
materi
mani
virus
great
import
transfus
medicin
although
detect
blood
necessarili
impli
infect
sinc
genet
materi
detect
furthermor
nonhuman
viral
speci
also
detect
blood
mani
individu
attribut
contamin
commerci
reagent
environ
nonetheless
identif
virus
sewageassoci
gemycircularviru
suggest
due
contamin
phlebotomi
plasma
pool
process
therefor
target
test
blood
product
might
best
econom
logist
option
ensur
blood
safeti
abl
show
effici
inactiv
merscov
therapeut
human
plasma
unit
log
far
expect
viral
load
merscov
human
blood
serum
describ
recent
studi
investig
inactiv
merscov
plasma
use
riboflavin
uv
light
studi
show
reduct
least
least
log
viral
titer
pool
individu
donor
plasma
respect
howev
passag
experi
pathogen
reduct
conduct
complet
inactiv
infecti
particl
taken
grant
sever
previou
studi
also
prove
effici
ib
inactiv
larg
number
pathogen
virus
bacteria
parasit
studi
describ
add
merscov
list
pathogen
inactiv
ib
taken
togeth
previous
publish
work
data
show
ib
could
repres
econom
logist
effici
protect
solut
reduc
risk
associ
circul
merscov
arabian
peninsula
potenti
transmiss
merscov
also
known
unknown
pathogen
commerci
avail
screen
assay
